Dupixent Shows Promise in Treating Atopic Dermatitis in Patients with Darker Skin Tones

Sanofi and Regeneron have announced positive results from a Phase IV study of Dupixent (dupilumab) in patients with atopic dermatitis and darker skin tones. The data highlights the biologic's efficacy in addressing the unique challenges faced by this patient population, further solidifying Dupixent's position as a leading treatment for inflammatory conditions.

Efficacy in Diverse Patient Populations

The study, which included 120 patients, predominantly of Black ethnicity (80%), demonstrated significant improvements in disease severity and quality of life measures. After 24 weeks of treatment:

• 76% of patients achieved at least a 75% improvement in overall disease severity
• More than half of the patients experienced itch relief
• A 53% reduction in post-inflammatory hyperpigmentation was observed
• The proportion of patients very or extremely bothered by dry skin decreased from 78% to 18%

These results are particularly noteworthy given the distinct manifestation of atopic dermatitis in patients with darker skin tones, which can include more severe skin dryness, prolonged discoloration, and hardened skin lesions.

Safety Profile and Mechanism of Action

Dupixent's safety profile in this study was consistent with its known profile for dermatology indications. Common side effects included headache, upper respiratory tract infections, and eye inflammation. As a monoclonal antibody, Dupixent works by blocking interleukin signaling, targeting the underlying type 2 inflammation associated with atopic dermatitis and other conditions.

Expanding Indications and Market Success

This latest data adds to Dupixent's growing list of approved indications and clinical successes. Recent developments include:

• FDA approval for chronic spontaneous urticaria (CSU) in April 2025, marking the first new targeted therapy for this condition in over a decade
• Becoming the first FDA-approved biologic for chronic obstructive pulmonary disease in September 2024
• Continued strong market performance, with 2024 sales exceeding $14 billion, representing 22% year-on-year growth

Dupixent's expanding portfolio of indications, which now includes asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and prurigo nodularis, underscores its versatility in treating inflammation-related conditions across various patient populations.